Clinical Trial Update: L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the L-DEP Regimen as salvage therapy for refractory EBV-induced Hemophagocytic Lymphohistiocytosis, with the current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• L-DEP Regimen

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: UNKNOWN